Pharmaceutical composition for the treatment of rhinitis
First Claim
1. A pharmaceutical composition for the prophylactic or curative topical treatment of rhinitis, said composition comprising in combination and in each case in pharmaceutically efficacious amounts:
- (a) at least one sympathomimetic suitable for topical application and having vasoconstrictor action or detumescent action on the mucous membrane or its physiologically acceptable salts or derivatives; and
(b) at least one acidic glycosaminoglycan or its physiologically acceptable salts or derivatives.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to a pharmaceutical composition suitable for the prophylactic and/or curative topical treatment of rhinitis, said composition containing in combination and in each case in pharmaceutically efficacious amounts: (a) at least one sympathomimetic suitable for topical application and having vasoconstrictor action and/or detumescent action on the mucous membrane or its physiologically acceptable salts or derivatives; and (b) at least one preferably acidic glycosaminoglycan or its physiologically acceptable salts or derivatives, in particular hyaluronic acid or its salts. On account of a synergistic combined action of the glycosaminoglycan with the sympathomimetic, drying out and inflammatory irritation of the nasal mucous membranes caused by the sympathomimetic on topical application of the pharmaceutical composition are avoided and a detumescence of the mucous membrane in the nasal cavity and an inhibition of secretion are simultaneously achieved, which leads to an efficient alleviation of rhinitis.
7 Citations
22 Claims
-
1. A pharmaceutical composition for the prophylactic or curative topical treatment of rhinitis, said composition comprising in combination and in each case in pharmaceutically efficacious amounts:
-
(a) at least one sympathomimetic suitable for topical application and having vasoconstrictor action or detumescent action on the mucous membrane or its physiologically acceptable salts or derivatives; and
(b) at least one acidic glycosaminoglycan or its physiologically acceptable salts or derivatives. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 19)
-
-
12. A pharmaceutical composition for the prophylactic or curative topical treatment of rhinitis, said composition comprising in combination and in each case in pharmaceutically efficacious amounts:
-
(a) at least one sympathomimetic suitable for topical application and having vasoconstrictor action or detumescent action on the mucous membrane or its physiologically acceptable salts or derivatives;
(b) at least one acidic glycosaminoglycan or its physiologically acceptable salts or derivatives; and
(c) at least one of pantothenol, its derivatives, pantothenic acid, or physiologically acceptable salts of pantothenic acid. - View Dependent Claims (13, 14, 20)
-
-
15. A pharmaceutical composition for the prophylactic or curative topical treatment of rhinitis, said composition comprising in combination and in each case based on the pharmaceutical composition:
-
(a) 0.001 to 1% by weight of at least one sympathomimetic suitable for topical application and having vasoconstrictor action or detumescent action on the mucous membrane or its physiologically acceptable salts or derivatives;
(b) 0.01 to 5% by weight of at least one acidic glycosaminoglycan or its physiologically acceptable salts or derivatives; and
(c) optionally 0.01 to 15% by weight of pantothenol or its derivatives and/or pantothenic acid or its physiologically acceptable salts. - View Dependent Claims (16, 17, 21)
-
-
18. A pharmaceutical composition for the prophylactic or curative topical treatment of rhinitis, comprising in combination and in each case based on the pharmaceutical composition
(a) 0.001 to 1% by weight of at least one sympathomimetic selected from the group consisting of oxymetazoline and xylometazoline; -
(b) 0.01 to 5% by weight of hyaluronic acid in the form of its physiologically acceptable salts; and
(c) optionally 0.01 to 15% by weight of at least one of pantothenol or its esters and/or pantothenic acid or its physiologically acceptable salts. - View Dependent Claims (22)
-
Specification